Tirdzniecība Sutro Biopharma, Inc. - STRO CFD
Pievienot izlasei- Kopsavilkums
- Vēsturiskie Dati
- Notikumi
- Peļņas Atskaite
- Bilance
- Naudas Plūsma
- Īpašums
Tirdzniecības Nosacījumi
| Starpība | 0.05 | ||||||||
|
Garās pozīcijas nodeva naktij
Long position overnight fee
Doties uz platformu | -0.025457% | ||||||||
|
Īsās pozīcijas nodeva naktij
Short position overnight fee
Doties uz platformu | 0.003235% | ||||||||
| Nakts laika nodeva | 21:00 (UTC) | ||||||||
| Min. tirgotais daudzums | 1 | ||||||||
| Valūta | USD | ||||||||
| Drošības rezerve | 20% | ||||||||
| Fondu birža | United States of America | ||||||||
| Tirdzniecības komisija | 0% |
*Information provided by Capital.com
Sutro Biopharma Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Galvenie Statistikas Dati
| Iepriekš. aizvērt* | 4.43 |
| Atvērt* | 4.44 |
| Izmaiņas par 1 gadu* | 5.71% |
| Dienas Diapazons* | 4.43 - 4.69 |
| 52 ned Diapazons | 3.33-8.72 |
| Vidējais apjoms (10 dienas) | 404.69K |
| Vidējais apjoms (3 mēneši) | 10.11M |
| Tirgus Kapitalizācija | 269.46M |
| Cenas/Peļņas Attiecība | -100.00K |
| Izvietotās Akcijas | 60.42M |
| Ieņēmumi | 74.55M |
| EPS | -2.38 |
| Dividende (Ienesīgums %) | N/A |
| Beta | 0.88 |
| Nākamās Peļņas Datums | Aug 7, 2023 |
"Visus datus nodrošina Refinitiv, izņemot datus, kas atzīmēti ar zvaigznīti, kas ir *dati, kurus nodrošina Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Aizvēršana | Change | Change (%) | Atvēršana | High | Low |
|---|---|---|---|---|---|---|
| Jun 2, 2023 | 4.69 | 0.41 | 9.58% | 4.28 | 4.70 | 4.28 |
| Jun 1, 2023 | 4.43 | 0.05 | 1.14% | 4.38 | 4.50 | 4.31 |
| May 31, 2023 | 4.48 | -0.10 | -2.18% | 4.58 | 4.68 | 4.41 |
| May 30, 2023 | 4.59 | -0.24 | -4.97% | 4.83 | 4.93 | 4.54 |
| May 26, 2023 | 4.87 | -0.06 | -1.22% | 4.93 | 5.18 | 4.86 |
| May 25, 2023 | 5.04 | 0.06 | 1.20% | 4.98 | 5.10 | 4.96 |
| May 24, 2023 | 5.09 | -0.14 | -2.68% | 5.23 | 5.37 | 5.04 |
| May 23, 2023 | 5.26 | 0.03 | 0.57% | 5.23 | 5.50 | 5.23 |
| May 22, 2023 | 5.28 | -0.01 | -0.19% | 5.29 | 5.57 | 5.27 |
| May 19, 2023 | 5.36 | 0.03 | 0.56% | 5.33 | 5.43 | 5.24 |
| May 18, 2023 | 5.25 | -0.27 | -4.89% | 5.52 | 5.64 | 5.13 |
| May 17, 2023 | 5.71 | 0.07 | 1.24% | 5.64 | 5.74 | 5.46 |
| May 16, 2023 | 5.71 | 0.35 | 6.53% | 5.36 | 6.07 | 5.35 |
| May 15, 2023 | 5.84 | 0.39 | 7.16% | 5.45 | 6.02 | 5.40 |
| May 12, 2023 | 5.62 | 0.43 | 8.29% | 5.19 | 5.65 | 5.19 |
| May 11, 2023 | 5.44 | -0.09 | -1.63% | 5.53 | 5.58 | 5.36 |
| May 10, 2023 | 5.57 | 0.14 | 2.58% | 5.43 | 5.64 | 5.43 |
| May 9, 2023 | 5.47 | 0.37 | 7.25% | 5.10 | 5.54 | 5.10 |
| May 8, 2023 | 5.47 | 0.03 | 0.55% | 5.44 | 5.55 | 5.35 |
| May 5, 2023 | 5.45 | 0.30 | 5.83% | 5.15 | 5.48 | 5.08 |
Sutro Biopharma, Inc. Events
| Laiks (UTC) (UTC) | Valsts | Notikums |
|---|---|---|
| Wednesday, June 7, 2023 | ||
| Laiks (UTC) (UTC) 20:30 | Valsts US
| Notikums Sutro Biopharma Inc at Jefferies Healthcare Conference Sutro Biopharma Inc at Jefferies Healthcare ConferenceForecast -Previous - |
| Thursday, June 8, 2023 | ||
| Laiks (UTC) (UTC) 19:00 | Valsts US
| Notikums Sutro Biopharma Inc Annual Shareholders Meeting Sutro Biopharma Inc Annual Shareholders MeetingForecast -Previous - |
| Monday, August 7, 2023 | ||
| Laiks (UTC) (UTC) 10:59 | Valsts US
| Notikums Q2 2023 Sutro Biopharma Inc Earnings Release Q2 2023 Sutro Biopharma Inc Earnings ReleaseForecast -Previous - |
| Monday, November 6, 2023 | ||
| Laiks (UTC) (UTC) 10:59 | Valsts US
| Notikums Q3 2023 Sutro Biopharma Inc Earnings Release Q3 2023 Sutro Biopharma Inc Earnings ReleaseForecast -Previous - |
- Ikgadējs
- Ceturkšņa
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 67.772 | 61.88 | 42.722 | 42.736 | 38.419 |
| Ienākumi | 67.772 | 61.88 | 42.722 | 42.736 | 38.419 |
| Kopējie Darbības Izdevumi | 196.715 | 160.404 | 113.779 | 98.204 | 75.642 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 59.544 | 56.004 | 36.818 | 32.592 | 21.38 |
| Pētniecība un Attīstība | 137.171 | 104.4 | 76.961 | 65.612 | 54.262 |
| Darbības Izdevumi | -128.943 | -98.524 | -71.057 | -55.468 | -37.223 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | 12.239 | -7.014 | 38.929 | -0.276 | -0.007 |
| Citi, Neto | 1.913 | ||||
| Neto Ienākumi Pirms Nodokļu Nomaksas | -116.704 | -105.538 | -32.128 | -55.744 | -35.317 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | -119.204 | -105.538 | -32.128 | -55.744 | -35.317 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | -119.204 | -105.538 | -32.128 | -55.744 | -35.317 |
| Neto Ienākumi | -119.204 | -105.538 | -32.128 | -55.744 | -35.317 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -119.204 | -105.538 | -32.128 | -55.744 | -35.317 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -119.204 | -105.538 | -32.128 | -55.744 | -35.317 |
| Atšķaidītie Neto Ienākumi | -119.204 | -105.538 | -32.128 | -55.744 | -35.317 |
| Atšķaidītie Ienākumi par Akcijām | 50.7392 | 46.1191 | 32.5735 | 22.9586 | 22.8482 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -2.34935 | -2.28838 | -0.98632 | -2.42803 | -1.54572 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Atšķaidītā Normalizētā Peļņa par Akciju | -2.34935 | -2.28838 | -0.98632 | -2.42803 | -1.54572 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 12.674 | 8.632 | 25.147 | 28.096 | 5.897 |
| Ienākumi | 12.674 | 8.632 | 25.147 | 28.096 | 5.897 |
| Kopējie Darbības Izdevumi | 54.911 | 57.854 | 46.357 | 47.475 | 45.029 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 15.512 | 14.719 | 14.643 | 15.143 | 15.039 |
| Pētniecība un Attīstība | 39.399 | 43.135 | 31.714 | 32.332 | 29.99 |
| Darbības Izdevumi | -42.237 | -49.222 | -21.21 | -19.379 | -39.132 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -7.418 | 14.628 | 1.722 | -4.133 | 0.022 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | -49.655 | -34.594 | -19.488 | -23.512 | -39.11 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | -50.05 | -34.594 | -19.488 | -26.012 | -39.11 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | -50.05 | -34.594 | -19.488 | -26.012 | -39.11 |
| Neto Ienākumi | -50.05 | -34.594 | -19.488 | -26.012 | -39.11 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -50.05 | -34.594 | -19.488 | -26.012 | -39.11 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -50.05 | -34.594 | -19.488 | -26.012 | -39.11 |
| Atšķaidītie Neto Ienākumi | -50.05 | -34.594 | -19.488 | -26.012 | -39.11 |
| Atšķaidītie Ienākumi par Akcijām | 58.7234 | 57.09 | 52.3457 | 46.9572 | 46.4996 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -0.8523 | -0.60596 | -0.37229 | -0.55395 | -0.84108 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Atšķaidītā Normalizētā Peļņa par Akciju | -0.8523 | -0.60596 | -0.37229 | -0.55395 | -0.84108 |
- Ikgadējs
- Ceturkšņa
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 353.153 | 218.515 | 378.182 | 128.568 | 209.946 |
| Nauda un Īstermiņa Ieguldījumi | 334.364 | 197.938 | 368.137 | 117.864 | 204.492 |
| Nauda un Ekvivalenti | 47.254 | 30.414 | 206.152 | 4.96 | 125.298 |
| Īstermiņa Ieguldījumi | 287.11 | 167.524 | 161.985 | 112.904 | 79.194 |
| Debitoru Parādu Kopsumma, Neto | 7.122 | 12.454 | 5.559 | 6.298 | 2.489 |
| Accounts Receivable - Trade, Net | 7.122 | 12.454 | 5.559 | 6.298 | 2.489 |
| Prepaid Expenses | 11.667 | 8.123 | 4.486 | 4.406 | 2.965 |
| Total Assets | 406.944 | 341.408 | 394.111 | 156.37 | 223.139 |
| Property/Plant/Equipment, Total - Net | 51.064 | 51.591 | 12.935 | 9.633 | 10.934 |
| Property/Plant/Equipment, Total - Gross | 88.969 | 85.017 | 49.762 | 43.481 | 40.23 |
| Accumulated Depreciation, Total | -37.905 | -33.426 | -36.827 | -33.848 | -29.296 |
| Other Long Term Assets, Total | 2.727 | 2.527 | 2.994 | 2.56 | 2.259 |
| Total Current Liabilities | 66.547 | 41.736 | 29.597 | 32.967 | 36.423 |
| Accounts Payable | 4.797 | 11.327 | 5.544 | 5.584 | 3.061 |
| Accrued Expenses | 32.491 | 12.454 | 8.823 | 6.017 | 6.217 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 12.5 | 9.375 | 0 | 1 | 4.724 |
| Other Current Liabilities, Total | 16.759 | 8.58 | 15.23 | 20.366 | 22.421 |
| Total Liabilities | 189.896 | 88.844 | 62.063 | 58.581 | 91.6 |
| Total Long Term Debt | 3.771 | 15.738 | 24.545 | 8.876 | 10 |
| Long Term Debt | 3.771 | 15.738 | 24.545 | 8.876 | 10 |
| Other Liabilities, Total | 119.578 | 31.37 | 7.921 | 16.738 | 45.177 |
| Total Equity | 217.048 | 252.564 | 332.048 | 97.789 | 131.539 |
| Redeemable Preferred Stock | 0 | 0 | |||
| Common Stock | 0.058 | 0.046 | 0.046 | 0.023 | 0.023 |
| Additional Paid-In Capital | 670.223 | 586.243 | 559.746 | 293.346 | 281.891 |
| Retained Earnings (Accumulated Deficit) | -452.615 | -333.411 | -227.873 | -195.745 | -150.328 |
| Other Equity, Total | -0.618 | -0.314 | 0.129 | 0.165 | -0.047 |
| Total Liabilities & Shareholders’ Equity | 406.944 | 341.408 | 394.111 | 156.37 | 223.139 |
| Total Common Shares Outstanding | 57.4995 | 46.3812 | 45.7521 | 23.099 | 22.8482 |
| Long Term Investments | 0 | 68.775 | 0 | 15.609 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 304.063 | 353.153 | 346.553 | 331.511 | 228.742 |
| Nauda un Īstermiņa Ieguldījumi | 276.494 | 334.364 | 324.248 | 225.636 | 209.145 |
| Nauda un Ekvivalenti | 62.472 | 47.254 | 96.779 | 79.115 | 28.901 |
| Īstermiņa Ieguldījumi | 214.022 | 287.11 | 227.469 | 146.521 | 180.244 |
| Debitoru Parādu Kopsumma, Neto | 9.873 | 7.122 | 11.241 | 97.671 | 11.686 |
| Accounts Receivable - Trade, Net | 9.873 | 7.122 | 11.241 | 97.671 | 11.686 |
| Prepaid Expenses | 17.696 | 11.667 | 11.064 | 8.204 | 7.911 |
| Total Assets | 358.016 | 406.944 | 400.7 | 385.62 | 303.675 |
| Property/Plant/Equipment, Total - Net | 49.831 | 51.064 | 51.354 | 51.316 | 51.657 |
| Long Term Investments | 0 | 0 | 0 | 20.699 | |
| Other Long Term Assets, Total | 4.122 | 2.727 | 2.793 | 2.793 | 2.577 |
| Total Current Liabilities | 59.486 | 66.547 | 58.288 | 44.572 | 38.76 |
| Accounts Payable | 5.058 | 4.797 | 12.443 | 12.567 | 10.705 |
| Accrued Expenses | 24 | 32.491 | 13.011 | 8.868 | 6.486 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 17.186 | 16.759 | 20.334 | 10.637 | 9.069 |
| Total Liabilities | 172.603 | 189.896 | 170.974 | 176.562 | 83.303 |
| Total Long Term Debt | 0 | 3.771 | 6.783 | 9.779 | 12.762 |
| Long Term Debt | 0 | 3.771 | 6.783 | 9.779 | 12.762 |
| Other Liabilities, Total | 113.117 | 119.578 | 105.903 | 122.211 | 31.781 |
| Total Equity | 185.413 | 217.048 | 229.726 | 209.058 | 220.372 |
| Common Stock | 0.06 | 0.058 | 0.055 | 0.049 | 0.047 |
| Additional Paid-In Capital | 688.125 | 670.223 | 649.028 | 608.898 | 593.998 |
| Retained Earnings (Accumulated Deficit) | -502.665 | -452.615 | -418.021 | -398.533 | -372.521 |
| Total Liabilities & Shareholders’ Equity | 358.016 | 406.944 | 400.7 | 385.62 | 303.675 |
| Total Common Shares Outstanding | 60.1618 | 57.4995 | 54.6314 | 48.6742 | 46.3271 |
| Current Port. of LT Debt/Capital Leases | 13.242 | 12.5 | 12.5 | 12.5 | 12.5 |
| Other Equity, Total | -0.107 | -0.618 | -1.336 | -1.356 | -1.152 |
- Ikgadējs
- Ceturkšņa
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Neto ienākumi/Sākuma Līnija | -119.204 | -105.538 | -32.128 | -55.744 | -35.317 |
| Nauda no Darbības | 3.549 | -81.679 | -67.802 | -65.023 | 12.683 |
| Nauda no Darbības | 5.69 | 4.844 | 4.297 | 4.777 | 4.539 |
| Bezskaidras Naudas Preces | 12.658 | 36.635 | -28.485 | 9.208 | 0.855 |
| Samaksātie Procenti Naudā | 1.869 | 2.046 | 1.675 | 1.049 | 1.275 |
| Izmaiņas Apgrozāmajā Kapitālā | 104.405 | -17.62 | -11.486 | -23.264 | 42.606 |
| Nauda no Ieguldījumu Darbībām | -35.022 | -97.315 | 0.604 | -51.131 | -80.19 |
| Kapitālie Izdevumi | -7.858 | -15.323 | -7.129 | -3.481 | -1.557 |
| Citi Ieguldījumu Naudas Plūsmas Posteņi, Kopā | -27.164 | -81.992 | 7.733 | -47.65 | -78.633 |
| Nauda no Darbībām ar Finansēšanu | 48.313 | 3.256 | 269.247 | -4.184 | 170.785 |
| Naudas Plūsma Finansēšanas Posteņos | -0.463 | 0.778 | -0.314 | 0.636 | 1.208 |
| Akciju Izsniegšana (Atkāpšanās), Neto | 58.151 | 2.478 | 254.561 | 0.18 | 169.577 |
| Neto Izmaiņas Naudā | 16.84 | -175.738 | 202.049 | -120.338 | 103.278 |
| Parādu Izsniegšana (Atkāpšanās), Neto | -9.375 | 0 | 15 | -5 | |
| Cash Taxes Paid | 0 | 0.103 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -50.05 | -119.204 | -84.61 | -65.122 | -39.11 |
| Cash From Operating Activities | -60.991 | 3.549 | 27.413 | -38.441 | -35.255 |
| Cash From Operating Activities | 1.615 | 5.69 | 4.162 | 2.724 | 1.327 |
| Non-Cash Items | 11.855 | 12.658 | 23.021 | 19.094 | 7.751 |
| Cash Interest Paid | 0.00039 | 1.869 | 1.442 | 0.998 | 0.504 |
| Changes in Working Capital | -24.411 | 104.405 | 84.84 | 4.863 | -5.223 |
| Cash From Investing Activities | 67.451 | -35.022 | 2.86 | 80.897 | 32.982 |
| Capital Expenditures | -0.942 | -7.858 | -4.491 | -3.753 | -1.553 |
| Other Investing Cash Flow Items, Total | 68.393 | -27.164 | 7.351 | 84.65 | 34.535 |
| Cash From Financing Activities | 8.758 | 48.313 | 36.092 | 6.245 | 0.76 |
| Financing Cash Flow Items | -0.451 | -0.463 | -0.463 | -0.413 | -0.426 |
| Issuance (Retirement) of Stock, Net | 12.334 | 58.151 | 42.805 | 9.783 | 1.186 |
| Issuance (Retirement) of Debt, Net | -3.125 | -9.375 | -6.25 | -3.125 | 0 |
| Net Change in Cash | 15.218 | 16.84 | 66.365 | 48.701 | -1.513 |
| Investora vārds | Investora veids | Nenokārtots procents | Akcijas turējumā | Izmaiņas akcijās | Turēšanas termiņš | Apgrozījuma reitings |
|---|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | Hedge Fund | 9.4164 | 5689086 | 123987 | 2023-03-31 | LOW |
| Rubric Capital Management LP | Hedge Fund | 7.2173 | 4360487 | 1148615 | 2023-03-31 | MED |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.5001 | 3927145 | 25108 | 2023-03-31 | LOW |
| BVF Partners L.P. | Hedge Fund | 5.5414 | 3347946 | 0 | 2023-03-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.8376 | 2922712 | 1071427 | 2023-03-31 | LOW |
| Franklin Advisers, Inc. | Investment Advisor/Hedge Fund | 4.6602 | 2815577 | -229 | 2023-03-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.5963 | 2776962 | 132290 | 2023-03-31 | LOW |
| Holocene Advisors, LP | Hedge Fund | 3.5303 | 2132873 | -180669 | 2023-03-31 | HIGH |
| Baillie Gifford & Co. | Investment Advisor | 3.0913 | 1867654 | -961 | 2023-03-31 | LOW |
| Candriam Belgium S.A. | Investment Advisor/Hedge Fund | 3.0799 | 1860775 | 1071591 | 2023-03-31 | LOW |
| Frazier Healthcare Partners | Venture Capital | 2.9404 | 1776479 | 0 | 2023-03-31 | LOW |
| Samsara BioCapital, LLC | Venture Capital | 2.7734 | 1675579 | 0 | 2023-03-31 | LOW |
| Candriam Luxembourg S.A. | Investment Advisor | 2.6949 | 1628181 | -60000 | 2023-04-30 | HIGH |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 1.9418 | 1173199 | 505656 | 2023-03-31 | LOW |
| Verition Fund Management LLC | Hedge Fund | 1.8965 | 1145786 | -458443 | 2023-03-31 | HIGH |
| Parkman Healthcare Partners LLC | Hedge Fund | 1.8207 | 1100038 | 234063 | 2023-03-31 | HIGH |
| Goldman Sachs Asset Management, L.P. | Investment Advisor | 1.7942 | 1084017 | 159429 | 2023-03-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.7484 | 1056314 | 35235 | 2023-03-31 | LOW |
| Kynam Capital Management LP | Hedge Fund | 1.4927 | 901836 | 497292 | 2023-03-31 | HIGH |
| Millennium Management LLC | Hedge Fund | 1.4758 | 891616 | -477405 | 2023-03-31 | HIGH |
Kāpēc izvēlēties Capital.com? Mūsu skaitļi runā paši par sevi.
Capital.com Group535K+
Tirgotāji
87K+
Ikmēneša aktīvie klienti
$113M+
Ikmēneša ieguldījumu apjoms
$64M+
Izņemts katru mēnesi
Treidinga kalkulators
Aprēķiniet iespējamo peļņu un zaudējumus, uzsākot CFD darījumu noteiktā dienā (izvēlaties datumu) un slēdzot darījumu citā dienā (izvēlaties datumu).
Tirdzniecības komisija
0
- 1:1
Finanšu svira
1:1
- 20
- 100
- 500
- 1000
- 10000
Investīcija
Darījuma apjoms (Kredītplecs x Investīcija):
Atvēršana
Aizvēršana
Īss Garšs
Sutro Biopharma, Inc. Company profile
Par Sutro Biopharma, Inc.
Sutro Biopharma, Inc. ir klīniskās stadijas zāļu atklāšanas, izstrādes un ražošanas uzņēmums. Tas koncentrējas uz integrētas bezšūnu proteīnu sintēzes un vietai specifiskas konjugācijas platformas XpressCF izmantošanu, lai radītu dažādas proteīnu terapijas, sākotnēji vēža ārstēšanai. Uzņēmums nodarbojas ar terapeitisko līdzekļu izstrādi, izmantojot iedarbīgas metodes, tostarp uz citokīniem balstītus terapeitiskos līdzekļus, imūnonkoloģijas līdzekļus, antivielu un zāļu konjugātus (ADC) un bispecifiskas antivielas, kas ir vērstas pret klīniski apstiprinātiem mērķiem. Uzņēmuma kandidātprodukti ir STRO-002 un STRO-001. STRO-002 ir ADC, kas vērsts pret folātu receptoru alfa, un paredzēts pacientiem ar FolRα ekspresijas vēzi, piemēram, olnīcu un endometrija vēzi. STRO-001 ir ADC, kas vērsts pret CD74 un paredzēts pacientiem ar B šūnu ļaundabīgiem audzējiem, piemēram, multiplo mielomu un ne-Hodžkina limfomu. Uzņēmuma kandidātprodukti ir izstrādāti un optimizēti terapeitiskā indeksa sasniegšanai, izvietojot savienotājgalviņas noteiktās antivielas vietās.
| Industry: | Bio Therapeutic Drugs |
111 Oyster Point Blvd.
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
Peļņas Atskaite
- Annual
- Quarterly
Cilvēki arī skatās
Vai joprojām meklējat mākleri, kuram varat uzticēties?
Pievienojieties 535 000+ tirgotājiem visā pasaulē, kuri izvēlējās tirgoties ar Capital.com